RPRX Stock Royalty Pharma (RPRX, $24.92) RSI Indicator left the oversold zone on December 20, 2024

GET DAILY SIGNALS

Get AI intraday signals

RPRX - Royalty Pharma plc

RSI signal

View

Odds of UP Trend

Price: $24.92

Daily change: +$0.64 (+2.64%)

Daily volume: 7.6M

Capitalization: $11.1B

Industry: Biotechnology

RPRX in upward trend: price rose above 50-day moving average on January 07, 2025

RPRX moved above its 50-day moving average on January 07, 2025 date and that indicates a change from a downward trend to an upward trend. In of 53 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on December 26, 2024. You may want to consider a long position or call options on RPRX as a result. In of 73 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for RPRX just turned positive on December 26, 2024. Looking at past instances where RPRX's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .

The 10-day moving average for RPRX crossed bullishly above the 50-day moving average on January 10, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RPRX advanced for three days, in of 245 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 11 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RPRX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

RPRX broke above its upper Bollinger Band on January 10, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for RPRX entered a downward trend on December 31, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.989) is normal, around the industry mean (14.746). P/E Ratio (12.106) is within average values for comparable stocks, (87.786). RPRX's Projected Growth (PEG Ratio) (6.673) is slightly higher than the industry average of (1.852). RPRX's Dividend Yield (0.027) is considerably higher than the industry average of (0.013). P/S Ratio (8.091) is also within normal values, averaging (263.573).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. RPRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.